The Calmer Co International Limited has reported its strongest quarterly revenue ever at $2.4 million, driven by robust Australian retail sales and expanding US market presence. The company is also advancing a $1.4 million convertible note to fuel growth and inventory expansion.
- Record quarterly revenue of $2.4 million, up 26% from prior quarter
- Australian retail sales surged 30%, led by Coles and Woolworths
- US sales increased 20%, boosted by new Amazon product launches
- B2B sales grew 20%, supported by strategic partners and IMCD’s Network Nutrition
- Secured $700,000 tranche of $1.4 million convertible note to support growth
Record-Breaking Quarter for The Calmer Co
The Calmer Co International Limited (ASX – CCO), a specialist in natural relaxation and sleep-support products, has announced a milestone quarter with record sales of $2.4 million for Q1 FY26. This represents a significant 26% increase over the previous quarter, underscoring the company’s accelerating momentum in both domestic and international markets.
Strong Australian Retail Performance
The Australian market remains a cornerstone of The Calmer Co’s growth story. Sales in Australia jumped 30% quarter-on-quarter to $1.4 million, driven primarily by expanded retail distribution through major supermarket chains Coles and Woolworths. This shift towards retail channels has proven more profitable than the company’s earlier e-commerce-focused approach, reflecting a maturing consumer base and stronger brand presence on physical shelves.Expanding US Footprint and B2B Growth
Across the Pacific, US sales climbed 20% to $936,000, buoyed by new product launches on Amazon. The company’s diversified sales strategy is paying dividends, with e-commerce platforms in both Australia and the US growing steadily but at a lower investment cost. Additionally, B2B sales rose 20% to $290,000, supported by increasing orders from strategic partners and IMCD’s Network Nutrition, highlighting the growing demand for The Calmer Co’s higher concentration kava extracts.Capital Raise to Fuel Next Phase
To sustain this growth trajectory, The Calmer Co has secured commitments for $700,000 as the first tranche of a proposed $1.4 million secured convertible note issuance. This capital injection is earmarked for wholesale inventory build and growth initiatives, positioning the company to maintain momentum and target breakeven in the near term. CEO Zane Yoshida emphasized the strategic importance of this funding, noting the validation it provides from key partners like Applied Food Sciences.Looking ahead, The Calmer Co’s product portfolio, including brands like Fiji Kava, Taki Mai, and Danodan Hempworks, continues to tap into a global trend favoring natural alternatives to alcohol and pharmaceutical sleep aids. With a reliable farm-to-shelf supply chain and expanding distribution networks, the company is well placed to capitalize on increasing consumer interest in wellness beverages.
Bottom Line?
With record sales and fresh capital secured, The Calmer Co is poised for its next growth chapter, but execution risks remain.
Questions in the middle?
- How will The Calmer Co balance growth investments with the path to breakeven?
- What impact will new product launches have on US market penetration long term?
- Can the company sustain retail momentum amid increasing competition in natural wellness?